首页 | 本学科首页   官方微博 | 高级检索  
检索        

丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床研究
引用本文:王御林,钟纯正,郭春宣,高元杰.丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床研究[J].中国医院用药评价与分析,2020(4):428-431.
作者姓名:王御林  钟纯正  郭春宣  高元杰
作者单位:儋州市人民医院神经内科
基金项目:海南省卫生计生行业科研项目(No.17A200079)。
摘    要:目的:探讨丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床疗效。方法:对儋州市人民医院2017年6月至2019年5月收治的116例急性进展性脑梗死患者进行回顾性研究,根据治疗方式的不同分为观察组、对照组,每组58例。对照组患者采用奥扎格雷钠注射液治疗,观察组患者采用丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗。比较两组患者临床疗效,治疗前后美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS)评分、Barthel指数及凝血因子水平变化和不良反应发生情况的差异。结果:观察组患者的总有效率为89.66%(52/58),明显高于对照组的74.14%(43/58),差异有统计学意义(P<0.05)。治疗后,两组患者NIHSS评分明显低于治疗前,Barthel指数明显高于治疗前;且观察组患者NIHSS评分明显低于对照组,Barthel指数明显高于对照组,上述差异均有统计学意义(P<0.05)。治疗后,两组患者活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)及国际标准化比值(INR)水平均明显高于治疗前,纤维蛋白原(FIB)水平明显低于治疗前;且观察组患者APTT、PT及INR水平明显高于对照组,FIB水平明显低于对照组,上述差异均有统计学意义(P<0.05)。观察组、对照组患者不良反应发生率13.79%(8/58)vs.10.34%(6/58)]的差异无统计学意义(P>0.05)。结论:丁苯酞氯化钠注射液联合奥扎格雷钠注射液治疗急性进展性脑梗死的临床疗效显著,可有效减轻患者神经功能受损现象,改善凝血功能。

关 键 词:丁苯酞氯化钠注射液  奥扎格雷钠注射液  急性进展性脑梗死  临床疗效  神经功能  凝血因子

Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction
WANG Yulin,ZHONG Chunzheng,GUO Chunxuan,GAO Yuanjie.Clinical Study of Butylphthalide and Sodium Chloride Injection Combined with Sodium Ozagrel Injection in the Treatment of Acute Progressive Cerebral Infarction[J].Evaluation and Analysis of Drug-Use in Hospital of China,2020(4):428-431.
Authors:WANG Yulin  ZHONG Chunzheng  GUO Chunxuan  GAO Yuanjie
Institution:(Dept. of Neurology, Danzhou People’s Hospital, Hainan Danzhou 571700, China)
Abstract:OBJECTIVE:To probe into the clinical efficacy of butylphthalide and sodium chloride injection combined with sodium ozagrel injection in the treatment of acute progressive cerebral infarction.METHODS:116 patients with acute progressive cerebral infarction admitted into Danzhou People’s Hospital from Jun.2017 to May 2019 were retrospectively analyzed and divided into observation group and control group according to different therapeutic regimens,with 58 cases in each group.The control group was treated with sodium ozagrel injection,while the observation group was given butylphthalide and sodium chloride injection combined with sodium ozagrel injection.The clinical efficacy,differences in National Institutes of Health Stroke Scale(NIHSS)scores,Barthel indices,changes of blood coagulation factor and incidences of adverse drug reactions of the two groups were compared.RESULTS:The total effective rate of observation group was 89.66%(52/58),which was significantly higher than that of the control group(74.14%,43/58),with statistically significant difference(P<0.05).After treatment,the NIHSS scores of both groups were significantly decreased,while the Barthel indices of both groups were significantly increased;the NIHSS score of observation group was significantly lower than that of the control group,while the Barthel index of observation group was significantly higher than that of the control group,with statistically significant differences(P<0.05).After treatment,the activated partial thromboplastin time(APTT),prothrombin time(PT)and international normalized ratio(INR)levels of both groups were significantly increased,while the fibrinogen(FIB)level was significantly decreased;the APTT,PT and INR levels of observation group were significantly higher than those of the control group,while the FIB level of observation group was significantly lower than that of the control group,with statistically significant differences(P<0.05).The incidences of adverse drug reactions of observation group and control group were respectively 13.79%(8/58)and 10.34%(6/58),the difference had no statistical significance(P>0.05).CONCLUSIONS:The clinical efficacy of butylphthalide and sodium chloride injection combined with sodium ozagrel injection in the treatment of acute progressive cerebral infarction is remarkable,which can effectively relieve the damage of neurological function and improve coagulation function.
Keywords:Butylphthalide and sodium chloride injection  Sodium ozagrel injection  Acute progressive cerebral infarction  Clinical efficacy  Neurological function  Coagulation factors
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号